A genetic variant in the CD226 gene that increases multiple sclerosis risk prevents immune cells from properly responding to vitamin D, blocking the creation of protective immune cells that normally prevent MS. According to Gram Research analysis, this 2026 study reveals that people carrying this genetic variant cannot activate a critical immune protein called LFA-1 when exposed to vitamin D, disrupting the normal protective pathway. This explains why some people with low vitamin D remain at high MS risk even with supplementation.
Scientists discovered how a genetic variation linked to multiple sclerosis (MS) interferes with vitamin D’s protective effects on the immune system. According to Gram Research analysis, the study reveals that people with a specific gene variant struggle to activate a type of immune cell that normally helps prevent MS when exposed to vitamin D. This finding explains why some people with low vitamin D are at higher risk for MS, even when they try to boost their levels. The research suggests that understanding this genetic-environmental interaction could lead to better treatments for MS patients.
Key Statistics
A 2026 study published in The Journal of Clinical Investigation found that the CD226 Gly307Ser genetic variant, which increases MS risk, impairs immune cells’ ability to activate the LFA-1 protein needed for vitamin D-induced protective cell development.
Research shows that MS patients carrying the CD226 risk variant cannot properly transform immune cells into protective regulatory cells (Tr1 cells) when exposed to vitamin D, even though this transformation normally occurs in healthy individuals.
According to the study, the MS-associated CD226 variant disrupts a critical immune pathway by preventing LFA-1 activation, which is essential for vitamin D to trigger the production of IL-10, an immune-calming chemical that protects against MS.
The Quick Take
- What they studied: How a specific genetic variant in the CD226 gene affects the immune system’s ability to use vitamin D to prevent multiple sclerosis
- Who participated: The study involved laboratory analysis of immune cells from people with MS and healthy controls, examining how genetic variants affect cell behavior when exposed to vitamin D
- Key finding: A genetic variant (Gly307Ser) that increases MS risk prevents immune cells from properly responding to vitamin D, blocking the creation of protective regulatory cells that normally suppress inflammation
- What it means for you: If you carry this genetic variant, simply taking vitamin D supplements may not provide the same protective benefits as it does for others. This could explain why some people with low vitamin D still develop MS despite supplementation, though more research is needed to confirm clinical applications
The Research Details
Researchers studied immune cells in the laboratory to understand how vitamin D works to protect against MS. They compared cells from people with MS to cells from healthy people, focusing on a specific genetic variation that appears in the CD226 gene. The team examined how this genetic variant affects a type of immune cell called regulatory T cells (Tr1 cells), which normally help calm down the immune system and prevent it from attacking the brain and spinal cord.
The scientists used advanced laboratory techniques to activate immune cells and expose them to vitamin D, then measured whether the cells developed into protective regulatory cells. They specifically looked at how a protein called LFA-1 on the cell surface helps trigger this protective transformation, and whether the genetic variant interferes with this process.
This approach allowed researchers to understand the step-by-step mechanism of how genes and vitamin D interact, rather than just observing that they’re connected. By breaking down the process into individual components, they could identify exactly where the genetic variant causes problems.
Understanding the exact mechanism, the ‘how’ and ‘why’, is crucial for developing targeted treatments. Rather than just knowing that a genetic variant increases MS risk, researchers can now design therapies that either bypass the problem or restore the broken pathway. This type of detailed mechanistic research is the foundation for precision medicine approaches in MS treatment.
This study was published in The Journal of Clinical Investigation, a highly respected peer-reviewed journal that publishes rigorous medical research. The research used established laboratory methods and focused on understanding biological mechanisms at the cellular level. However, this is laboratory-based research, not a clinical trial in humans, so the findings need to be tested in actual patients before they can change medical practice. The study provides important foundational science that explains why certain genetic variants increase MS risk.
What the Results Show
The research shows that people carrying the MS-risk variant of the CD226 gene have immune cells that cannot properly respond to vitamin D. Normally, when immune cells are exposed to vitamin D and a specific immune signal (CD46 stimulation), they transform into protective regulatory cells that produce a calming chemical called IL-10. This transformation prevents the immune system from attacking the brain and spinal cord.
However, in cells carrying the genetic risk variant, this protective transformation doesn’t happen effectively. The vitamin D signal gets blocked at a critical step: the cells cannot properly activate a protein called LFA-1 on their surface. LFA-1 acts like a switch that turns on the protective regulatory cell program. Without proper LFA-1 activation, the cells stay in an inflammatory state instead of becoming protective.
The researchers also found that MS patients’ immune cells, even those without the genetic variant, show this same problem with LFA-1 activation. This suggests that the genetic variant may be one of several ways that MS disrupts this protective pathway. The findings indicate that both genetic predisposition and the disease itself can interfere with vitamin D’s protective effects.
The study revealed that the specific genetic variant (Gly307Ser) works by changing how the CD226 protein functions on the cell surface. This altered protein cannot effectively signal to activate LFA-1, creating a bottleneck in the protective pathway. The research also suggests that MS patients may have additional problems beyond just this genetic variant that prevent proper regulatory cell development, indicating that MS involves multiple broken mechanisms rather than a single cause.
Previous research established that vitamin D deficiency increases MS risk and that vitamin D can help immune cells become protective. This study builds on that knowledge by explaining why vitamin D doesn’t work equally well for everyone. It connects genetic susceptibility to environmental factors (vitamin D exposure) in a concrete, mechanistic way. The findings support the idea that MS results from both genetic predisposition and environmental factors working together, rather than either one alone being sufficient to cause disease.
This research was conducted in laboratory cell cultures, not in living people, so the findings need confirmation through clinical studies. The study doesn’t tell us how common this genetic variant is in the general population or how much it contributes to overall MS risk. Additionally, the research focuses on one specific genetic variant and one specific immune pathway; MS is a complex disease involving many genes and immune mechanisms. The findings also don’t address whether other factors (like infections, sun exposure, or other environmental triggers) might overcome or worsen this genetic effect.
The Bottom Line
Current evidence does not support changing vitamin D supplementation practices based on this research alone. People with MS or at risk for MS should continue following their doctor’s recommendations for vitamin D levels. However, if you carry this genetic variant (which can be determined through genetic testing), your doctor may need to consider additional or alternative treatments beyond vitamin D supplementation to achieve the same protective effect. More clinical research is needed before specific recommendations can be made.
This research is most relevant to people with MS, people with a family history of MS, and people living in areas with limited sun exposure (which increases MS risk). It’s also important for MS researchers and neurologists developing new treatments. People without MS or genetic risk factors for MS may benefit from standard vitamin D recommendations but don’t need to change their approach based on this research. Anyone considering genetic testing for MS risk should discuss this with their healthcare provider.
This research is foundational science that explains biological mechanisms. It will likely take 3-5 years of additional clinical research before new treatments based on these findings become available. In the meantime, people with MS should continue their current vitamin D and MS treatment plans as prescribed by their neurologist.
Frequently Asked Questions
Does vitamin D prevent multiple sclerosis in everyone?
Vitamin D helps reduce MS risk for most people, but a 2026 study found that people with a specific genetic variant (CD226 Gly307Ser) don’t respond as well to vitamin D. Their immune cells cannot properly activate protective mechanisms when exposed to vitamin D, suggesting genetic factors determine how effective vitamin D supplementation is for MS prevention.
Can I get genetic testing to see if I have the MS-risk CD226 variant?
Genetic testing for MS-risk variants is available through specialized medical centers and research programs, though it’s not yet routine clinical practice. If you have MS or strong family history of MS, ask your neurologist whether genetic testing might be helpful for your care. This emerging research may eventually lead to more personalized testing recommendations.
What should I do if I have low vitamin D and MS risk?
Continue working with your doctor to maintain adequate vitamin D levels through supplementation and sun exposure, as vitamin D remains protective for most people. However, if you have MS and your symptoms aren’t improving despite good vitamin D levels, discuss with your neurologist whether additional immune-modulating treatments might be necessary, since genetic factors may limit vitamin D’s effectiveness for some patients.
How does this research change MS treatment?
This research is foundational science that explains why vitamin D doesn’t work equally for everyone with MS. It suggests future treatments might need to target the LFA-1 pathway directly or use alternative approaches for people with the CD226 risk variant. Clinical applications are likely 3-5 years away pending additional research.
Is this genetic variant common in people with MS?
The study doesn’t specify how common this variant is among MS patients, but it’s identified as an MS-risk variant in genetic studies. Not all MS cases involve this variant, MS is complex with many genetic and environmental factors involved. Genetic testing would be needed to determine if you carry this specific variant.
Want to Apply This Research?
- Track your vitamin D blood levels (measured in ng/mL) monthly if you have MS or MS risk factors. Record the date, your vitamin D level, and any MS symptoms or relapses. This helps identify whether your vitamin D supplementation is achieving target levels (typically 30-50 ng/mL for MS patients) and whether additional treatments might be needed.
- If you have MS or genetic risk for MS, work with your doctor to establish a vitamin D supplementation plan and schedule regular blood tests to monitor levels. Set a daily reminder to take your supplement consistently, and log your intake in the app. If your levels aren’t reaching target despite supplementation, discuss with your neurologist whether additional immune-modulating treatments might be necessary.
- Create a quarterly review in your app comparing your vitamin D levels, supplementation dose, sun exposure, and MS symptom patterns. This long-term tracking helps you and your doctor identify whether your current vitamin D strategy is effective or whether adjustments are needed. Share this data with your healthcare team to inform personalized treatment decisions.
This research describes laboratory findings about how genetic variants affect immune cell behavior. It does not provide clinical guidance for MS treatment or vitamin D supplementation. People with MS or at risk for MS should continue following their neurologist’s recommendations for vitamin D levels and MS treatment. Genetic testing for MS-risk variants is not yet standard clinical practice. This article is for educational purposes and should not replace professional medical advice. Consult your healthcare provider before making changes to your vitamin D supplementation or MS treatment plan based on this research.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
